Four months after going public on the strength of its GR-II receptor antagonists, Corcept Therapeutics Inc. reached agreement on a special protocol assessment for pivotal Phase III trials to test its lead product Corlux (mifepristone) against the psychotic features of major depression. (BioWorld Today)

To those who don't know better, "naked short selling" might conjure the image of an online day trader, tapping away on his keyboard in the nude. Many who do know better wish they didn't, since the reality of the illegal practice is much less amusing - especially for companies on the wrong end of the deals, such as smaller-cap biotechnology firms.